Indoxyl sulfate induces left ventricular hypertrophy
aryl hydrocarbon receptor
fibroblast growth factor 23
fibroblast growth factor receptor 4
indoxyl sulfate
left ventricular hypertrophy
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
07
2022
accepted:
18
01
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Patients with chronic kidney disease (CKD) have a high risk of left ventricular hypertrophy (LVH). Fibroblast growth factor 23 (FGF23) and indoxyl sulfate (IS) are associated with LVH in patients with CKD, but the interactions between these molecules remain unknown. We investigated whether IS contributes to LVH associated with FGF23 in cultured cardiomyocytes and CKD mice. In cultured rat cardiac myoblast H9c2 cells incubated with IS, mRNA levels of the LVH markers atrial natriuretic factor, brain natriuretic peptide, and β-myosin heavy chain were significantly upregulated. Levels of mRNA of the polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3), which regulates FGF23 O-glycosylation, and FGF23 were also upregulated in H9c2 cells. Intact FGF23 protein expression and fibroblast growth factor receptor 4 (FGFR4) phosphorylation were increased in cell lysates by IS administration. In C57BL/6J mice with heminephrectomy, IS promoted LVH, whereas the inhibition of FGFR4 significantly reduced heart weight and left ventricular wall thickness in IS-treated groups. While there was no significant difference in serum FGF23 concentrations, cardiac FGF23 protein expression was markedly increased in IS-injected mice. GALNT3, hypoxia-inducible factor 1 alpha, and FGF23 protein expression was induced in H9c2 cells by IS treatment and suppressed by the inhibition of Aryl hydrocarbon receptor which is the receptor for IS. This study suggests that IS increases FGF23 protein expression via an increase in GALNT3 and hypoxia-inducible factor 1 alpha expression, and activates FGF23-FGFR4 signaling in cardiomyocytes, leading to LVH.
Sections du résumé
Background
UNASSIGNED
Patients with chronic kidney disease (CKD) have a high risk of left ventricular hypertrophy (LVH). Fibroblast growth factor 23 (FGF23) and indoxyl sulfate (IS) are associated with LVH in patients with CKD, but the interactions between these molecules remain unknown. We investigated whether IS contributes to LVH associated with FGF23 in cultured cardiomyocytes and CKD mice.
Methods and results
UNASSIGNED
In cultured rat cardiac myoblast H9c2 cells incubated with IS, mRNA levels of the LVH markers atrial natriuretic factor, brain natriuretic peptide, and β-myosin heavy chain were significantly upregulated. Levels of mRNA of the polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3), which regulates FGF23 O-glycosylation, and FGF23 were also upregulated in H9c2 cells. Intact FGF23 protein expression and fibroblast growth factor receptor 4 (FGFR4) phosphorylation were increased in cell lysates by IS administration. In C57BL/6J mice with heminephrectomy, IS promoted LVH, whereas the inhibition of FGFR4 significantly reduced heart weight and left ventricular wall thickness in IS-treated groups. While there was no significant difference in serum FGF23 concentrations, cardiac FGF23 protein expression was markedly increased in IS-injected mice. GALNT3, hypoxia-inducible factor 1 alpha, and FGF23 protein expression was induced in H9c2 cells by IS treatment and suppressed by the inhibition of Aryl hydrocarbon receptor which is the receptor for IS.
Conclusion
UNASSIGNED
This study suggests that IS increases FGF23 protein expression via an increase in GALNT3 and hypoxia-inducible factor 1 alpha expression, and activates FGF23-FGFR4 signaling in cardiomyocytes, leading to LVH.
Identifiants
pubmed: 36895836
doi: 10.3389/fcvm.2023.990422
pmc: PMC9988908
doi:
Types de publication
Journal Article
Langues
eng
Pagination
990422Informations de copyright
Copyright © 2023 Kishimoto, Nakano, Torisu, Tokumoto, Uchida, Yamada, Taniguchi and Kitazono.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Kidney Int. 2008 Jun;73(11):1296-302
pubmed: 18337714
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Nephrol Dial Transplant. 2016 Jul;31(7):1088-99
pubmed: 26681731
Nephrol Dial Transplant. 2009 Oct;24(10):3125-31
pubmed: 19429932
Front Cell Dev Biol. 2016 Apr 13;4:30
pubmed: 27148532
J Am Coll Cardiol. 2003 Jan 1;41(1):47-55
pubmed: 12570944
N Engl J Med. 2008 Aug 7;359(6):584-92
pubmed: 18687639
J Leukoc Biol. 2013 Jun;93(6):837-45
pubmed: 23362306
Calcif Tissue Int. 2021 Jul;109(1):66-76
pubmed: 33616712
Circulation. 2009 May 19;119(19):2545-52
pubmed: 19414634
Nephrol Dial Transplant. 2017 Sep 01;32(9):1493-1503
pubmed: 28339837
Nat Chem Biol. 2020 Mar;16(3):351-360
pubmed: 31932717
Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8
pubmed: 19696217
Kidney Int. 1989 Aug;36(2):286-90
pubmed: 2528654
J Am Soc Nephrol. 2002 Jul;13(7):1918-27
pubmed: 12089389
Int J Mol Sci. 2019 Sep 18;20(18):
pubmed: 31540546
Biochemistry. 2010 Jan 19;49(2):393-400
pubmed: 20000589
Int J Mol Sci. 2020 Mar 22;21(6):
pubmed: 32235720
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1146-55
pubmed: 22006328
Oncotarget. 2016 Oct 4;7(40):64649-64664
pubmed: 27579618
Kidney Int. 2003 May;63(5):1934-43
pubmed: 12675874
Nephrol Dial Transplant. 2021 Feb 20;36(3):442-451
pubmed: 33241290
J Am Soc Nephrol. 2007 Sep;18(9):2600-8
pubmed: 17656479
Inflamm Cell Signal. 2014;1(5):
pubmed: 26082935
J Pharm Sci. 2011 Sep;100(9):3682-95
pubmed: 21538353
Cells. 2019 Jan 09;8(1):
pubmed: 30634399
Kidney Int. 2016 Jan;89(1):135-46
pubmed: 26535997
Kidney Int. 2005 Jul;68(1):228-36
pubmed: 15954912
Nephrol Dial Transplant. 2010 Dec;25(12):3983-9
pubmed: 20525642
Cell Metab. 2015 Dec 1;22(6):1020-32
pubmed: 26437603
J Clin Invest. 2011 Nov;121(11):4393-408
pubmed: 21985788
Toxicol Sci. 2014 Jun;139(2):301-16
pubmed: 24614234
Toxins (Basel). 2015 Aug 14;7(8):3155-66
pubmed: 26287243
J Am Soc Nephrol. 2002 Mar;13(3):745-753
pubmed: 11856780
Am J Kidney Dis. 2012 Jan;59(1 Suppl 1):A7, e1-420
pubmed: 22177944
Circulation. 2019 Jan 2;139(1):78-96
pubmed: 30586693
J Am Soc Nephrol. 2005 Feb;16(2):520-8
pubmed: 15615819